Navigation Links
Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA

AMSTERDAM, The Netherlands, June 24 /PRNewswire/ -- The U.S. Department of Energy's Pacific Northwest National Laboratory has signed an agreement with Avantium to enable the sale and delivery of an Avantium Flowrence(TM) parallel fixed bed reactor system. The Flowrence(TM) will allow PNNL to accelerate its catalyst research for infrastructure compatible biofuels and bioproducts.

PNNL is operated by Battelle for the U.S. Department of Energy. The Laboratory advances science and develops solutions for global challenges at the energy and environment nexus. PNNL scientists have extensive expertise in catalysis and reaction engineering, with particular focus on solutions for efficient use of bioproducts, converting biomass and renewable feedstocks to fuels and chemicals, and reducing environmental emissions.

The Avantium system will be housed in the Bioproducts, Sciences and Engineering Laboratory (BSEL). BSEL is a multipurpose research and development facility that includes operating space for all activities required to advance the science and engineering of processes for bio-based product manufacture. The building is located on the campus of Washington State University Tri-Cities Campus in Richland, Washington, approximately one mile south of the main campus of PNNL.

Tom van Aken, Chief Executive Officer of Avantium: "The sale of Flowrence(TM) platforms to a world leading research center such as PNNL is a recognition of the value of Avantium's proprietary high-throughput R&D technology. We are proud to provide our unique Flowrence technology to PNNL to help increase PNNL's R&D productivity significantly with our methodology."

Avantium's proprietary parallel fixed bed rector technology has been successfully applied for over 9 years in collaboration programs for gas, liquid and trickle flow applications (e.g. hydrotreating, VGO hydrocracking, selective oxidation and selective hydrogenation). The Flowrence(TM) is Avantium's proprietary commercially available parallel fixed bed reactor system. The system consists of 16 reactors (4 blocks of 4 reactors each) tailored to the clients applications enabling them to enhance their catalysis research and process optimization efforts. Flowrence(TM) enables users to test catalytic materials for a range of chemistries under industrial processing conditions, including high-temperature (up to 850 0C) and high-pressure reactions (up to 180 Bar).

Profile Avantium

Avantium is a leading technology company specialized in the area of advanced high-throughput R&D. The company develops and commercializes Furanics, a next generation biofuels and bioplastics, and develops improved forms of existing drugs. Avantium has demonstrated the value and commercial potential of its unique technology and knowledge by collaborating with leading companies in the energy, chemical and pharmaceutical industry. Avantium's customer base for its R&D services and systems offering consists of more than 70 companies worldwide, including market leaders such as BP, Shell, Sasol, Pfizer and GSK. Avantium has around 140 employees; its offices and headquarters are based in Amsterdam, the Netherlands.


For more information about Flowrence(TM), including downloads and pictures, please visit Flowrence(TM) is a trademark of Avantium.

SOURCE Avantium Technologies B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avantium Completes EUR 18 Million Financing Round
2. Cosun and Avantium Announce Collaboration
3. Avantium Launches the Crystalline, a New Parallel System for Crystallization Research
4. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
7. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
8. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
9. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
10. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
11. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):